Dermatology · Investigational
Argireline (Acetyl Hexapeptide-8)
No lawful US pathway
01 · Overview
Argireline is a synthetic six amino acid peptide (Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2) patterned on the N-terminal end of the SNAP-25 protein and designed to mimic the action of botulinum toxin (PMID 23417317). In laboratory studies it interfered with formation or stability of the SNARE complex that drives neurotransmitter release, with far lower efficacy than botulinum toxin A (PMID 18498523).
It is used as a topical cosmetic ingredient for expression lines, but its hydrophilic nature and size limit skin penetration, and whether it reaches neuromuscular junctions when applied topically remains uncertain (PMID 40565185).
02 · Research summary & key findings
The developers reported that a cream containing the hexapeptide reduced wrinkle depth by up to 30 percent after 30 days in healthy women, in a small study without detailed controls (PMID 18498523). A randomized placebo-controlled study of 60 Chinese subjects published in a dermatology journal found significant reductions in periorbital wrinkle roughness after 4 weeks of twice-daily application, with no improvement on placebo (PMID 23417317). A 2025 review concluded that preclinical and clinical studies suggest benefits for wrinkle depth and hydration, but the mechanism of topical action remains incompletely understood and larger rigorous trials are lacking (PMID 40565185).
03 · Regulatory status
Argireline (Acetyl Hexapeptide-8) is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.
No lawful pathway today
Argireline (Acetyl Hexapeptide-8) is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so we do not sell it and will not book a consultation for it. That can change: in 2026 FDA began reviewing several peptides for compounding. If you are working on the goal it is studied for, a licensed clinician can tell you what is lawfully available, which may be something else.
See the 1 FDA-approved compound in Dermatology
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Looking for a lawful, clinician-prescribed option for longevity and healthy ageing?
Argireline (Acetyl Hexapeptide-8) is an investigational compound, is not FDA-approved, and has no lawful US compounding pathway, so we do not offer it and no clinician we work with will prescribe it. Products sold online as “research chemicals” are not made or tested to the standards required of medicines. If you are working on longevity and healthy ageing, a licensed clinician can tell you at a free consultation whether an FDA-approved or lawfully compounded treatment fits you, or whether nothing does.
Explore lawful options (free intake)About 3 minutes. If a protocol is prescribed through our provider, we earn 10% of the sale. See the receipts.
04 · Administration routes
- Topical
References
- [1]A synthetic hexapeptide (Argireline) with antiwrinkle activity Int J Cosmet Sci, 2002. PMID 18498523
- [2]The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study Am J Clin Dermatol, 2013. PMID 23417317
- [3]Acetyl Hexapeptide-8 in Cosmeceuticals-A Review of Skin Permeability and Efficacy Int J Mol Sci, 2025. PMID 40565185
Primary literature
- PubMed: "Argireline"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Argireline"
Registered interventional and observational studies, including status and phase.
- PubChem: "Argireline"
Chemical structure, molecular properties, and bioactivity data.
Related peptides in Dermatology
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.